

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (Review of TA619) [ID3779]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No
2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
NA
3. Has any change to the draft scope been agreed to highlight potential equality issues?
NA
4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

**Approved by Associate Director (name):** Janet Robertson

**Date:** 13 January 2022